Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 1:7:25.
doi: 10.3389/fonc.2017.00025. eCollection 2017.

Lenvatinib for Anaplastic Thyroid Cancer

Makoto Tahara  1 , Naomi Kiyota  2 , Tomoko Yamazaki  1 , Naoko Chayahara  2 , Kenji Nakano  3 , Lina Inagaki  3 , Kazuhisa Toda  4 , Tomohiro Enokida  1 , Hironobu Minami  2 , Yoshinori Imamura  2 , Tatsuya Sasaki  5 , Takuya Suzuki  5 , Katsuki Fujino  5 , Corina E Dutcus  6 , Shunji Takahashi  3
Affiliations

Lenvatinib for Anaplastic Thyroid Cancer

Makoto Tahara et al. Front Oncol. .

Abstract

Background: Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest lethality. Effective therapy for ATC is an unmet need.

Patients and methods: This phase 2, single-arm, open-label study in patients with thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted from 3 September 2012 to 9 July 2015. Patients received lenvatinib 24 mg daily until disease progression or development of unacceptable toxicity. The primary endpoint was safety, and the secondary endpoint was efficacy, as assessed by progression-free survival (PFS), overall survival (OS), and objective response rate.

Results: At data cutoff, 17 patients with ATC were enrolled. All experienced ≥1 treatment-emergent adverse event (TEAE). The most frequent TEAEs were decreased appetite (82%), hypertension (82%), fatigue (59%), nausea (59%), and proteinuria (59%). Of note, only one patient required lenvatinib withdrawal because of a TEAE, and this TEAE was considered unrelated to lenvatinib. The median PFS was 7.4 months [95% confidence interval (CI): 1.7-12.9], the median OS was 10.6 months (95% CI: 3.8-19.8), and the objective response rate was 24%.

Conclusion: In this study, lenvatinib demonstrated manageable toxicities with dose adjustments and clinical activity in patients with ATC. This clinical activity of lenvatinib warrants further investigation in ATC.

Clinicaltrialsgov: NCT01728623.

Keywords: anaplastic thyroid cancer; clinical trial; lenvatinib; phase 2; tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition and reason for discontinuation from study treatment.
Figure 2
Figure 2
Percentage change from baseline in summed tumor diameter.
Figure 3
Figure 3
Time to response and durability of response for patients with anaplastic thyroid cancer treated with lenvatinib.
Figure 4
Figure 4
Percentage change in tumor size from baseline with duration of lenvatinib treatment in patients with anaplastic thyroid cancer.
Figure 5
Figure 5
Computed tomography scans of a representative patient with anaplastic thyroid cancer at baseline and during treatment with lenvatinib.
See this image and copyright information in PMC

References

    1. Dumke AK, Pelz T, Vordermark D. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol (2014) 9(1):90.10.1186/1748-717X-9-90 - DOI - PMC - PubMed
    1. Perri F, Lorenzo GD, Scarpati GD, Buonerba C. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol (2011) 2(3):150–7.10.5306/wjco.v2.i3.150 - DOI - PMC - PubMed
    1. Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab (2012) 97(8):2566–72.10.1210/jc.2012-1314 - DOI - PMC - PubMed
    1. Denaro N, Nigro CL, Russi EG, Merlano MC. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther (2013) 9:1231–41.10.2147/OTT.S46545 - DOI - PMC - PubMed
    1. Ekman ET, Lundell G, Tennvall J, Wallin G. Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am (1990) 23(3):523–7. - PubMed

Associated data